Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
Tóm tắt
Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. In the phase III MONALEESA-2 study (NCT01958021), 668 patients were randomized 1:1 to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. PROs were assessed using the European Organisation for Research and Treatment of Cancer core quality-of-life (EORTC QLQ-C30) and breast cancer-specific (EORTC QLQ-BR23) questionnaires. Changes from baseline and time to deterioration in health-related quality of life (HRQoL) were analyzed using linear mixed-effect and stratified Cox regression models, respectively. Exploratory analysis of area-under-the-curve for change from baseline in pain score (AUC-pain) was performed.
On-treatment HRQoL scores were consistently maintained from baseline and were similar between arms. A clinically meaningful (> 5 points) reduction in pain score was observed as early as Week 8 and was maintained up to Cycle 15 in the ribociclib arm. A statistically significant increase in mean AUC-pain was also observed in the ribociclib arm. Scores for all other EORTC QLQ-C30 and EORTC QLQ-BR23 domains were maintained from baseline and were similar between arms. HRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2− advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population.
Tài liệu tham khảo
Kim S, Loo A, Chopra R et al (2013) LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6– reactivating Rb in cancer. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Abstract PR02
Parasuraman S, Caponigro G, Loo A et al (2014) LEE011, a potent and selective CDK4/6 inhibitor, under preclinical and clinical investigation. In: Targeted Anticancer Therapies Congress: Abstract O4.4
O’Brien N, Di Tomaso E, Ayala R et al (2014) In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research: Abstract 4756
Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748
Hortobagyi GN, Stemmer SM, Burris HA et al (2016) First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2−), advanced breast cancer (ABC). In: The 41st European Society of Medical Oncology Cancer Congress: Abstract LBA1_PR
Hortobagyi GN, Stemmer SM, Burris HA et al (2017) Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. In: American Society of Clinical Oncology Annual Meeting: Abstract 1038
Miles D, von Minckwitz G, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13–19
Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925–1936
Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Breast 31:244–259
Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
Sprangers MA, Groenvold M, Arraras JI et al (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756–2768
Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
Verma S, O’Shaughnessy J, Burris H et al (2017) Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2. In: American Society of Clinical Oncology Annual Meeting: Abstract 1020
Janni W, Alba E, Bachelot T et al (2018) First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2− advanced breast cancer: tumour response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4658-x
King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555–567
Wallwiener M, Simoes E, Sokolov AN et al (2016) Health-related quality of life in metastatic and adjuvant breast cancer patients. Geburtshilfe Frauenheilkd 76:1065–1073
Kovic B, Guyatt G, Brundage M et al (2016) Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol. BMJ Open 6:e012909
Montazeri A (2008) Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 27:32
Burris HA 3rd, Lebrun F, Rugo HS et al (2013) Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119:1908–1915
Hollen PJ, Msaouel P, Gralla RJ (2015) Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. Breast Cancer Res Treat 151:679–686
Cramarossa G, Chow E, Zhang L et al (2013) Predictive factors for overall quality of life in patients with advanced cancer. Support Care Cancer 21:1709–1716
Ripamonti CI, Santini D, Maranzano E et al (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23(Suppl 7):vii139–vii154